INSL3 Expression in Leydig Cell Hyperplasia and Leydig Cell Tumors.


Journal

Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796

Informations de publication

Date de publication:
03 2019
Historique:
pubmed: 31 10 2017
medline: 18 4 2020
entrez: 31 10 2017
Statut: ppublish

Résumé

Insulin-like 3 (INSL3) is a hormone produced by Leydig cells (LCs) and leads to physiological testicular descent during embryonic development. We investigated the expression of INSL3 by immunohistochemistry in normal LCs, in Leydig cell tumor (LCT) (n=17 including 15 testes and 2 ovaries) and in Leydig cell hyperplasia (LCH) (n=10). Normally distributed LCs showed strong immunostaining in the cytoplasm in all cases. All 10 cases (100%) of LCH were strongly and diffusely positive in the intertubular areas. Six cases of LCH had nodules raging in size from 0.2 to 0.9 cm with variable INSL3 staining. Fifteen of 17 (88.2%) LCTs showed marked decrease INSL3 staining, 10/17 (58.8%) were completely negative, and 5/17 (29.4%) were only focally positive. Two cases with multifocal LCTs showed strong and diffuse cytoplasmic staining of LCs around seminiferous tubules while the LCTs were negative. Two cases diagnosed as LCT were strongly positive for INSL3. Other sex cord stromal tumors tested were consistently negative including Sertoli-cell tumor (n=4), granulosa cell tumor (n=2), and fibrothecoma (n=1). In conclusion, our results contrast with those of previously published studies, and show that the great majority of LCTs are negative or have decreased expression of INSL3 while its expression is retained in LCH. INSL3 negative nodules within LCH may represent early LCTs. INSL3 immunostaining could be helpful to highlight LCs in cases where it is difficult to identify them (ie, small testicular biopsies performed for infertility workup) and in the differential diagnosis between florid LCH and LCT.

Identifiants

pubmed: 29084059
doi: 10.1097/PAI.0000000000000567
doi:

Substances chimiques

Biomarkers, Tumor 0
Insulin 0
Leydig insulin-like protein 0
Neoplasm Proteins 0
Proteins 0

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

203-209

Auteurs

Nelli S Lakis (NS)

Department of Pathology, The Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, RI.

Kara A Lombardo (KA)

Department of Pathology, The Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, RI.

Shamlal Mangray (S)

Department of Pathology, The Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, RI.

George J Netto (GJ)

Department of Pathology, University of Alabama, Birmingham, AL.
Departments of Pathology, The Johns Hopkins Hospital, Baltimore, MD.

Daniela Salles (D)

Departments of Pathology, The Johns Hopkins Hospital, Baltimore, MD.

Andres Matoso (A)

Departments of Pathology, The Johns Hopkins Hospital, Baltimore, MD.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH